Building Collaborative Oncology Utilization Management Through Multidisciplinary Practice Engagement
Background
Global spending on oncology therapies increased 75% from 2019 to 2024 and is projected to exceed $440 billion by 2029. Utilization management (UM) programs help promote evidence-based care and avoid unnecessary spending through tools such as prior authorization, clinical pathways, and prospective review, but are often criticized for administrative burden and strained payer-provider relationships. Evolent's multidisciplinary oncology UM model was designed to improve outcomes through evidence-based treatment management, collaborative provider engagement, and support for value-based oncology care.
Methods
The model integrates oncologists, oncology pharmacists, and practice performance advisors (PPAs) within a coordinated team. In addition to prospective utilization review, team members engage oncology practices through recurring performance reviews and feedback sessions. Prospective review evaluates alignment of proposed regimens with clinical evidence and oncology pathways at treatment planning. Oncologists and oncology pharmacists conduct clinically informed peer-to-peer (P2P) discussions for complex or non-pathway cases, while PPAs provide operational support and practice-level guidance. Key metrics include pathway adherence, authorization efficiency, P2P volume and outcomes, dose rounding acceptance, auto-approval rates, tumor reassessments, and checkpoint inhibitor utilization.
Results
Across Evolent's national oncology network, engaged practices demonstrated improvement in multiple value-based performance measures. Over 11 quarters, a minimally engaged practice (defined as having no quarterly performance reviews) experienced a decline in dose-rounding performance from 49.2% to 40.9%, whereas a highly engaged practice improved from 22.0% to 96.0%. During the same period, greater engagement was associated with increased pathway and preferred drug list (PDL) adherence, contributing to improvements in auto-approval (AA) rates; notably, 2 highly engaged practices increased AA rates from approximately 30% to more than 60%. These findings demonstrate that sustained partnership with a multidisciplinary utilization management (UM) team can enhance pathway adherence, operational efficiency, and delivery of high-value oncology care. High-performing practices may also become eligible for Evolent's Fast Pass program, a gold-carding approach designed to reduce administrative burden and expedite authorization decisions.
At a large academic cancer center, direct pharmacist-to-pharmacist collaboration enabled resolution of treatment authorization barriers. All P2P interventions over two quarters resulted in same-daypathway-aligned treatment modifications or avoidance of therapy denial, preserving therapeutic intent and preventing delays in care. The collaboration also improved pathway adherence, reduced regimen customization, and enhanced operational efficiency. Exchange of preferred drug information supported implementation of a payer-specific biosimilar interchange within the electronic medical record, enabling preferred biosimilars to be selected at the point of prescribing.
Practice engagement evolved from reactive utilization review to proactive collaboration through pathway addition requests and oncology conference debriefs.
Conclusion
A multidisciplinary oncology UM model integrating oncologists, oncology pharmacists, and PPAs provides a clinically driven approach to utilization management. By integrating evidence-based prospective review with bidirectional practice engagement, the model improved pathway adherence, operational efficiency, and provider engagement, supporting value-based oncology care.
Author Information
Authors:
Danielle E. Otto, PharmD, BCOP1; Elizabeth Travers, PharmD, BCOP1; Amy VanGalder, PharmD, BCOP1; Sang Chau, PharmD, BCOP1; Justin Tse, PharmD, BCOP1; Terra Wonsettler, PharmD, MBA1; Andrew Hertler, MD, FACP1
Affiliation:
1Evolent Health
Sponsor
N/A
References
- Tibau A, Vokinger KN, Kesselheim AS, Hwang TJ. High cost of cancer medicines in the United States: opportunities for policy reforms. JCO Oncol Pract. 2026;22(8):1374-1379. Doi:10.1200/OP-26-0032
- Institute of Medicine (US) Committee on Utilization Management by Third Parties; Gray BH, Field MJ, eds. Controlling Costs and Changing Patient Care? The Role of Utilization Management. National Academies Press;1989.


